A Phase 1 Study of JADE101 in Healthy Participants

November 11, 2026 updated by: Jade Biosciences, Inc.

A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JADE101 Administered Subcutaneously in Healthy Volunteers

This is a Phase 1, first-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of JADE101 compared to placebo in healthy participants.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This is a single center, Phase 1, double-blind, placebo-controlled, randomized, first-in-human (FIH), single ascending dose study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of JADE101 in healthy participants. The study will enroll approximately 32 healthy volunteers. JADE101 will be administered by a subcutaneous injection. The results of this study will help inform the dosing and frequency of dosing in future studies of JADE101.

Study Type

Interventional

Enrollment (Actual)

32

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Healthy male or female participants 18-55 years of age, inclusive
  2. A body weight between 50-100 kg and a body mass index (BMI) between 18.0 - 32.0 kg/m2 (all inclusive) at screening
  3. Willing and able to comply with the study site stay, scheduled visits, and study procedures
  4. Willing and able to comply with using two methods of contraception (one being highly effective) and lifestyle requirements from admission through the end of the study

Exclusion Criteria:

  1. Harmful alcohol use
  2. Smoking/vaping or heavy tobacco use within 2 years prior to screening
  3. Known history of abuse of illicit drugs
  4. Nursing, lactating or pregnant, or who have plans to become pregnant during the study
  5. Known history of clinically significant disease
  6. Known history of immunodeficiency disorder
  7. History of clinically significant allergic reactions or hypersensitivity

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: JADE101

Subcutaneous (SC) injection of JADE101

JADE101 is supplied as sterile solution to be administered by SC injection.

Placebo Comparator: Placebo

Subcutaneous (SC) injection of placebo

Placebo solution to be administered at a matching volume by SC injection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety and Tolerability of Single Ascending Doses of JADE101 in Healthy Participants
Time Frame: Day 1 through 48 weeks

Incidence of treatment-emergent adverse events

Day 1 through 48 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cmax
Time Frame: Day 1 through 48 weeks

Maximum observed serum concentration

Day 1 through 48 weeks
Tmax
Time Frame: Day 1 through 48 weeks

Time to reach Cmax

Day 1 through 48 weeks
AUClast
Time Frame: Day 1 through 48 weeks

The area under the concentration-time curve from time zero to the time of the last observed quantifiable (non-zero) concentration

Day 1 through 48 weeks
T1/2
Time Frame: Day 1 through 48 weeks

Apparent first-order terminal elimination half-life

Day 1 through 48 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Li Li, MD, Jade Biosciences, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 17, 2025

Primary Completion (Actual)

October 21, 2026

Study Completion (Actual)

October 21, 2026

Study Registration Dates

First Submitted

June 27, 2025

First Submitted That Met QC Criteria

July 9, 2025

First Posted (Actual)

July 10, 2025

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • JADE101-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.